Display options
Cite
Pech V, Abusaada K, Alemany C. Dipeptidyl Peptidase-4 Inhibition May Stimulate Progression of Carcinoid Tumor. Case Rep Endocrinol. 2015;2015:952019doi: 10.1155/2015/952019.
Pech, V., Abusaada, K., & Alemany, C. (2015). Dipeptidyl Peptidase-4 Inhibition May Stimulate Progression of Carcinoid Tumor. Case reports in endocrinology, 2015952019. https://doi.org/10.1155/2015/952019
Pech, Vladimir, et al. "Dipeptidyl Peptidase-4 Inhibition May Stimulate Progression of Carcinoid Tumor." Case reports in endocrinology vol. 2015 (2015): 952019. doi: https://doi.org/10.1155/2015/952019
Pech V, Abusaada K, Alemany C. Dipeptidyl Peptidase-4 Inhibition May Stimulate Progression of Carcinoid Tumor. Case Rep Endocrinol. 2015;2015:952019. doi: 10.1155/2015/952019. Epub 2015 Jul 28. PMID: 26290759; PMCID: PMC4531174.
Copy Download .nbib Format: NLM
Share it on

Case Rep Endocrinol. 2015;2015:952019. doi: 10.1155/2015/952019. Epub 2015 Jul 28.

Dipeptidyl Peptidase-4 Inhibition May Stimulate Progression of Carcinoid Tumor.

Case reports in endocrinology

Vladimir Pech, Khalid Abusaada, Carlos Alemany

Affiliations

  1. Internal Medicine Residency Program, Florida Hospital, 2501 N. Orange Avenue, Suite 235, Orlando, FL 32804, USA.
  2. Cancer Institute of Florida, Florida Hospital, 2501 N. Orange Avenue, Suite 235, Orlando, FL 32804, USA.

PMID: 26290759 PMCID: PMC4531174 DOI: 10.1155/2015/952019

Abstract

Dipeptidyl peptidase-4 (DPP-4) inhibitors, such as saxagliptin, have gained a rapid growth in use in the treatment of type 2 diabetes mellitus in the past decade. Although they are considered to have a good safety profile, controversy exists regarding their potential to stimulate neoplasm growth. We report here a patient with metastatic carcinoid tumor. His disease was stable for several years with plasma serotonin level (which was used to monitor disease progression) in 700-800 ng/mL range. After initiation of treatment with saxagliptin, however, his serotonin level almost doubled (1358 ng/mL), concerning progression of the disease. After discontinuation of saxagliptin, serotonin level returned to baseline quickly, while other laboratory markers, such as complete blood count (CBC), comprehensive metabolic profile (CMP) with liver function tests (LFTs), and lactate dehydrogenase (LD), remained unchanged before, during, and after the treatment with saxagliptin. This temporal correlation suggests a possible interaction between the activity of carcinoid tumors and the use of DPP-4 inhibitors. Although we were not able to find any literature providing a direct evidence that saxagliptin alters progression of the carcinoid tumors, we recommend alternative management for the treatment of diabetes in patients with carcinoid or other neuroendocrine tumors.

References

  1. N Engl J Med. 2011 Feb 10;364(6):501-13 - PubMed
  2. J Endocrinol. 2014 Mar 07;221(1):T43-61 - PubMed
  3. Expert Opin Drug Saf. 2015 Apr;14(4):505-24 - PubMed
  4. Am J Physiol Renal Physiol. 2012 Dec 15;303(12):F1584-91 - PubMed
  5. Gastrointest Cancer Res. 2008 May;2(3):113-25 - PubMed
  6. Endocr Relat Cancer. 2012 Sep 05;19(5):F77-88 - PubMed
  7. N Engl J Med. 2011 Feb 10;364(6):514-23 - PubMed
  8. Endocrinol Metab Clin North Am. 2011 Mar;40(1):1-18, vii - PubMed
  9. Cancer. 2008 Jul 1;113(1):5-21 - PubMed
  10. Dis Markers. 2013;35(6):825-32 - PubMed

Publication Types